These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11121879)

  • 1. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.
    Yasojima K; Akiyama H; McGeer EG; McGeer PL
    Neurosci Lett; 2001 Jan; 297(2):97-100. PubMed ID: 11121879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.
    Fukami S; Watanabe K; Iwata N; Haraoka J; Lu B; Gerard NP; Gerard C; Fraser P; Westaway D; St George-Hyslop P; Saido TC
    Neurosci Res; 2002 May; 43(1):39-56. PubMed ID: 12074840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.
    Yasojima K; McGeer EG; McGeer PL
    Brain Res; 2001 Nov; 919(1):115-21. PubMed ID: 11689168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques.
    Apelt J; Ach K; Schliebs R
    Neurosci Lett; 2003 Mar; 339(3):183-6. PubMed ID: 12633883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition.
    Akiyama H; Kondo H; Ikeda K; Kato M; McGeer PL
    Brain Res; 2001 Jun; 902(2):277-81. PubMed ID: 11384622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.
    Carpentier M; Robitaille Y; DesGroseillers L; Boileau G; Marcinkiewicz M
    J Neuropathol Exp Neurol; 2002 Oct; 61(10):849-56. PubMed ID: 12387451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neprilysin and amyloid beta peptide degradation.
    Hersh LB; Rodgers DW
    Curr Alzheimer Res; 2008 Apr; 5(2):225-31. PubMed ID: 18393807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging.
    Wang DS; Lipton RB; Katz MJ; Davies P; Buschke H; Kuslansky G; Verghese J; Younkin SG; Eckman C; Dickson DW
    J Neuropathol Exp Neurol; 2005 May; 64(5):378-85. PubMed ID: 15892294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.
    Hemming ML; Patterson M; Reske-Nielsen C; Lin L; Isacson O; Selkoe DJ
    PLoS Med; 2007 Aug; 4(8):e262. PubMed ID: 17760499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains.
    Liu Y; Hua Q; Lei H; Li P
    J Ethnopharmacol; 2011 Sep; 137(2):1035-46. PubMed ID: 21798326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
    Higuchi M; Iwata N; Saido TC
    Biochim Biophys Acta; 2005 Aug; 1751(1):60-7. PubMed ID: 16054018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
    Devi L; Ohno M
    Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease.
    Mohajeri MH; Kuehnle K; Li H; Poirier R; Tracy J; Nitsch RM
    FEBS Lett; 2004 Mar; 562(1-3):16-21. PubMed ID: 15043995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
    Tomita T
    Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form.
    Kanemitsu H; Tomiyama T; Mori H
    Neurosci Lett; 2003 Oct; 350(2):113-6. PubMed ID: 12972166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients.
    Marcinkiewicz M
    J Neuropathol Exp Neurol; 2002 Sep; 61(9):815-29. PubMed ID: 12230328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic regulation of brain Abeta by neprilysin.
    Iwata N; Tsubuki S; Takaki Y; Shirotani K; Lu B; Gerard NP; Gerard C; Hama E; Lee HJ; Saido TC
    Science; 2001 May; 292(5521):1550-2. PubMed ID: 11375493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging.
    Russo R; Borghi R; Markesbery W; Tabaton M; Piccini A
    FEBS Lett; 2005 Nov; 579(27):6027-30. PubMed ID: 16226260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.